Evotec is proud to be part of a new global collaboration of philanthropic, non-profit and private sector organizations who will work together to accelerate the development of novel TB treatment regimens for all TB patients.

The aim is to create treatment regimens comprised of medicines to which there is limited or no drug resistance and that are ready for phase 3 development. The members of the Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) – Evotec, GSK, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., the Bill & Melinda Gates Medical Research Institute and the Bill & Melinda Gates Foundation – have committed to leveraging their unique assets, resources and scientific expertise to advance the development of novel regimens.

Find out more about it on #WorldTBDay here